Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1856725 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $0.82Day +1.14%Mkt cap $54M1Y +48.7%Off 52W high −78.8%Vol (1Y) 276.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,247 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.4% of sh out |
| Days to cover11.3d |
| 13F net flow (QoQ)−4.03% |
| Top-10 13F concentration89.1% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.2M |
| Earnings (TTM)-$29.4M |
| ROE−169.6% |
| Net margin−1817.1% |
| Debt / equity0.00× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−39.3% |
| 1Y+48.7% |
| 3Y−80.8% |
| Since incept. (ann.)−40.3% |
Total return through 2026-07-28 · series begins 2021-08-02. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)276.1% |
| Ann. volatility (3Y)181.0% |
| Sharpe (1Y)0.82 |
| Sharpe (3Y)0.25 |
| Max drawdown (1Y)−77.8% |
| Max drawdown (3Y)−94.8% |
| Beta (3Y vs SPY)1.29 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8.5M | $6M | 12.85% | +0.0% |
| SAMSARA BIOCAPITAL, LLC | 8.5M | $6M | 12.85% | +0.0% |
| AWM Investment Company, Inc. | 6.5M | $5M | 9.83% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $3M | 6.99% | new |
| SymBiosis Capital Partners, LLC | 3.7M | $3M | 5.55% | −41.8% |
| Longaeva Partners L.P. | 2.3M | $2M | 3.52% | +10.2% |
| Siren, L.L.C. | 2.0M | $1M | 3.02% | +0.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 903,298 | $664,060 | 1.37% | +4.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.04 | — | $1.7M | +893.0% |
| 2025-12-31 | 2026-03-26 | — | — | $1.5M | +42.1% |
| 2025-09-30 | 2025-11-06 | −$0.12 | — | $0 | — |
| 2025-06-30 | 2025-08-07 | −$0.18 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
